CA2690815A1 - Targeted cell death - Google Patents

Targeted cell death Download PDF

Info

Publication number
CA2690815A1
CA2690815A1 CA2690815A CA2690815A CA2690815A1 CA 2690815 A1 CA2690815 A1 CA 2690815A1 CA 2690815 A CA2690815 A CA 2690815A CA 2690815 A CA2690815 A CA 2690815A CA 2690815 A1 CA2690815 A1 CA 2690815A1
Authority
CA
Canada
Prior art keywords
cell
protein
animal
caspase
cdmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2690815A
Other languages
English (en)
French (fr)
Inventor
Stephen M. Selkirk
Robert H. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2690815A1 publication Critical patent/CA2690815A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
CA2690815A 2007-06-12 2008-06-12 Targeted cell death Abandoned CA2690815A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94344807P 2007-06-12 2007-06-12
US60/943,448 2007-06-12
PCT/US2008/066774 WO2008154644A1 (en) 2007-06-12 2008-06-12 Targeted cell death

Publications (1)

Publication Number Publication Date
CA2690815A1 true CA2690815A1 (en) 2008-12-18

Family

ID=40130220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690815A Abandoned CA2690815A1 (en) 2007-06-12 2008-06-12 Targeted cell death

Country Status (7)

Country Link
US (4) US20100299770A1 (enExample)
EP (1) EP2167688A4 (enExample)
JP (2) JP2010531638A (enExample)
AU (1) AU2008261644B2 (enExample)
CA (1) CA2690815A1 (enExample)
IL (4) IL202701A (enExample)
WO (1) WO2008154644A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690815A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
EP2473031A4 (en) * 2009-09-02 2013-12-04 Univ Chicago METHOD AND SYSTEMS FOR THE INDUCIBLE ABERMENTATION OF NERVE CELLS
US8269827B2 (en) * 2009-09-29 2012-09-18 General Electric Company System and methods for mapping fluorescent images into a bright field color space
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013070079A2 (en) * 2011-11-10 2013-05-16 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk, miRNA IN BLOOD BRAIN BARRIER OF MS PATIENTS
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
KR20160002848A (ko) 2013-03-24 2016-01-08 오이신 바이오테크놀로지스 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법
US12331086B2 (en) * 2016-11-14 2025-06-17 Toolgen Incorporated Artificially engineered SC function control system
WO2018129563A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
JP7592493B2 (ja) 2018-04-18 2024-12-02 オイシン バイオテクノロジーズ，インク． 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
CN115197989A (zh) * 2021-04-09 2022-10-18 中国科学院分子细胞科学卓越创新中心 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US6677311B1 (en) * 1988-07-20 2004-01-13 The Salk Institute For Biological Studies Inducible HSV-TK in transformed cell populations
FR2637803B1 (fr) * 1988-10-19 1993-07-09 Ire Celltarg Sa Ligands specifiques de recepteurs d'hormones steroides estrogenes et progestagenes, application et produits intermediaires de synthese
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1994029442A2 (en) * 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
ES2198479T3 (es) * 1995-03-09 2004-02-01 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Vectores que llevan genes terapeuticos codificantes de peptidos antimicrobianos para terapia genica.
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US5837837A (en) * 1997-02-27 1998-11-17 Millennium Pharmaceuticals, Inc. Nucleic acids molecules encoding Caspase-8h and Caspase-8i
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US20030110524A1 (en) * 1997-07-28 2003-06-12 Bradley Michael John Stringer Transgenic organisms and their uses
US6982082B1 (en) * 1997-08-27 2006-01-03 President And Fellows Of Harvard College Gene therapy by cell specific targeting
US6984635B1 (en) * 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US6235872B1 (en) * 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
US7033595B1 (en) * 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
EP1131470A4 (en) * 1998-10-28 2004-11-10 Vysis Inc CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS
WO2000026343A2 (en) * 1998-10-30 2000-05-11 Case Western Reserve University Tissue specific promoters and transgenic animals for the screening of pharmaceuticals
US7109317B1 (en) * 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
US6903244B1 (en) * 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
US6881555B2 (en) * 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
US6890726B1 (en) * 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
JP2004500197A (ja) * 2000-02-08 2004-01-08 コーネル　リサーチ　ファンデーション　インコーポレーテッド 光ファイバーを通じた蛍光分光用の多光子励起
US7196182B2 (en) * 2000-05-24 2007-03-27 The Burnham Institute Card domain containing polypeptides, encoding nucleic acids, and methods of use
WO2002005634A2 (en) * 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
US6891081B1 (en) * 2000-08-14 2005-05-10 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
WO2002019814A2 (en) * 2000-09-07 2002-03-14 California Institute Of Technology Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety
US6967725B2 (en) * 2000-10-13 2005-11-22 Lucent Technologies Inc. System and method for optical scanning
AU2002239538A1 (en) * 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
CA2435829A1 (en) * 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US7169564B1 (en) * 2001-06-26 2007-01-30 Anaderm Research Corporation FKBP51/52 and CyP40-mediated mammalian hair growth
AU2003219769A1 (en) * 2002-02-14 2003-09-04 The Procter And Gamble Company Disposable excreta collector
US7153685B2 (en) * 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
US20060030541A1 (en) * 2002-04-05 2006-02-09 Proskelia Genes involved in osteogenesis, and methods of use
WO2004005531A2 (en) * 2002-07-05 2004-01-15 Roger Williams Medical Center Targeting and tracking of cells to specific organs and tissues in vivo
US20050143330A1 (en) * 2002-09-30 2005-06-30 Ron Mandel Method for the treatment of Parkinson's Disease
US7638331B2 (en) * 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
EP1711597B1 (en) * 2004-01-14 2012-03-07 Novahep AB Human hepatic progenitor cells and methods of use thereof
WO2006029161A2 (en) * 2004-09-07 2006-03-16 The Board Of Regents For Oklahoma State University Cell specific gene silencing using cell-specific promoters in vitro and in vivo
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis
EP1710316A1 (en) * 2005-04-08 2006-10-11 Max-Delbrück-Centrum Für Molekulare Medizin Reconstructed human mariner transposon capable of stable gene transfer into chromosomes in vertebrates
US7423194B2 (en) * 2005-06-14 2008-09-09 University Of Chicago Animal models for demyelination disorders
EP1909562A4 (en) 2005-06-14 2015-04-08 Univ Chicago METHOD FOR TREATING MYELIN LOSS STATES
CA2690815A1 (en) * 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death

Also Published As

Publication number Publication date
US20120198574A1 (en) 2012-08-02
US20090019554A1 (en) 2009-01-15
IL221851A0 (en) 2012-10-31
IL202701A0 (en) 2011-08-01
IL221853A0 (en) 2012-10-31
US8124749B2 (en) 2012-02-28
US20140033334A1 (en) 2014-01-30
JP2013081480A (ja) 2013-05-09
AU2008261644B2 (en) 2014-04-03
EP2167688A4 (en) 2010-07-28
IL202701A (en) 2012-12-31
US20100299770A1 (en) 2010-11-25
EP2167688A1 (en) 2010-03-31
US8704037B2 (en) 2014-04-22
JP2010531638A (ja) 2010-09-30
WO2008154644A1 (en) 2008-12-18
AU2008261644A1 (en) 2008-12-18
IL221852A0 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
AU2008261644B2 (en) Targeted cell death
JP2010531638A5 (enExample)
Mori et al. Inducible gene deletion in astroglia and radial glia—a valuable tool for functional and lineage analysis
Zhuo et al. hGFAP‐cre transgenic mice for manipulation of glial and neuronal function in vivo
Yin et al. Neurochemical properties of BDNF-containing neurons projecting to rostral ventromedial medulla in the ventrolateral periaqueductal gray
Wasserman et al. Muscarinic control of rostromedial tegmental nucleus GABA neurons and morphine‐induced locomotion
JP2022084573A (ja) 新しいアルツハイマー病動物モデル
Drexler et al. Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling
Rusielewicz et al. Accelerated repair of demyelinated CNS lesions in the absence of non‐muscle myosin IIB
Ducrot et al. Conditional deletion of neurexins dysregulates neurotransmission from dopamine neurons
Handa et al. The neural pathway from the superior subpart of the medial habenula to the interpeduncular nucleus suppresses anxiety
US20120233713A1 (en) Methods and systems for inducible ablation of neural cells
US20080109914A1 (en) Differential labeling of cells
Heldt et al. The use of lentiviral vectors and Cre/loxP to investigate the function of genes in complex behaviors
Oberto et al. The murine Y1 receptor 5′ upstream sequence directs cell‐specific and developmentally regulated LacZ expression in transgenic mice CNS
AU2014201772A1 (en) Targeted cell death
US8512678B2 (en) Non-invasive, in vivo fluorescent imaging of the nervous system in whole living animal
WO2007117573A2 (en) Transgenic mice for identifying and assessing neural stem/ progenitor cells
Takahashi Investigating the Involvement of GABAergic Interneurons and a Gene Therapy Strategy for Epilepsy in CLN2 Disease
Giraudet et al. Adeno-associated virus delivered Cre recombinase as a versatile strategy for modeling focal neuronal lesions
Caprariello Cytoarchitectural Defects Secondary To Experimentally Induced Oligodendrocyte Death In The Adult And Developing Central Nervous System
Ma Dependence of synaptic plasticity and memory facilitation upon amyloid precursor protein intracellular domain
Arguello The Impact of Chronic Morphine on Adult Hippocampal Progenitor Cells and the Neurogenic Niche
Wasserman The Central Role of RMTg GABA Neurons in Morphine-induced Locomotion
Park VRPD Novel Combinatory Approaches to Repair Visual System After Optic Nerve Damage

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130610

FZDE Discontinued

Effective date: 20150826